IGH/BCL2 Plus Translocation, Dual Fusion
This is a recurrent rearrangement of IGH in CLL1 and is cytogenetically indistinguishable from the t(14;18) translocation observed in follicular lymphoma.
The translocation (t(14;18)(q32.33;q21.33)) is thought to be brought about by an error in the joining function of the IGH gene, mediated by the observation that both IGH and BCL2 are arranged next to each other in 3D space in normal B lymphocytes2. The translocation breakpoint at the end of the Joining (J) segment, and the subsequent fusion of the BCL2 gene to this region, results in the BCL2 gene coming under the regulatory control of those processes normally involved in maintenance of IGH gene activity. The protein encoded by the BCL2 gene has been shown to be involved in the regulation of apoptosis.
Not only do Cytocell offer an extensive range of high-quality FISH probes, the customer support is also excellent — providing fast access to all the probes I need. The probes are highly consistent with bright signals allowing easy scoring of results. Dr Eric Crawford, Senior Director, Genetics Associates Inc.
1. Baseggio et al., Br J Haematol. 2012 Aug;158(4):489-98
2. Roix et al., Nature Genetics 2003;34(3):287-91
- Area of Interest*
- CLL, Lymphoma
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.